Home - AMDA Pompe
MHRA marketing authorization granted to Amicus' Pompe disease treatment
Amicus' Opfolda wins positive CHMP opinion in Pompe Disease - Pharmaceutical Technology
Amicus releases phase 3 results in Pompe disease trial
Amicus fail dents Pompe pipeline | Evaluate
Brandon Tom on LinkedIn: Congrats to Amicus Therapeutics on this new therapy for Pompe disease!
New Pompe disease treatment 'exciting,' Amicus chairman says
After FDA Discussions, Amicus Therapeutics to Push Pompe Disease Program into Phase II | BioSpace
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union - Canadian Association of Pompe
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics' Pombiliti + Opfolda for Treatment of Pompe Disease | Muscular Dystrophy Association
UK approval for Pompe Disease therapy
Curing Pompe and Helping His Kids the Mission of Amicus CEO
Bando: Opportunity to Spotlight Your Research in Pompe Disease
Amicus muscles in on Pompe gene therapy chase | Evaluate
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
FDA OKs Amicus Pompe combo, setting up market battle with Sanofi
FDA approves Amicus' combination therapy for LOPD
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease | Amicus Therapeutics
Amicus CEO John Crowley Outlines Progress in Fabry, Pompe, Batten Therapies | Fabry Disease News
Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA - Canadian Association of Pompe
Amicus Therapeutics wins EC approval of Opfolda for Pompe disease | Seeking Alpha
Convegno AIG 2021 - L'impegno di Amicus Therapeutics nella malattia di Pompe - YouTube
